Evidence map›Paper›PMID 35352796›Full record

ArticleAge and ageing2022

Characterising older adults' risk of harm from blood-pressure lowering medications: a sub-analysis from the PRIME study.

Ahmed Hussain, Khalid Ali, Nikesh Parekh, Jennifer M Stevenson, J Graham Davies, Stephen Bremner, Chakravarthi Rajkumar, PRIME study group

Open access · hybridAbstract read
In one paragraph

Article in Age and ageing, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Ahmed HussainDepartment of Elderly Medicine, University Hospitals Sussex NHS Foundation Trust, Sussex, UK.
Khalid AliDepartment of Elderly Medicine, University Hospitals Sussex NHS Foundation Trust, Sussex, UK.
Nikesh ParekhDepartment of Elderly Medicine, University Hospitals Sussex NHS Foundation Trust, Sussex, UK.
Jennifer M StevensonInstitute of Pharmaceutical Science, King's College London, London, UK.
J Graham DaviesInstitute of Pharmaceutical Science, King's College London, London, UK.
Stephen BremnerDepartment of Primary Care and Public Health, Brighton and Sussex Medical School, University of Sussex, Brighton, East Sussex, UK.
Chakravarthi RajkumarDepartment of Elderly Medicine, University Hospitals Sussex NHS Foundation Trust, Sussex, UK.
PRIME study group
Brighton and Sussex Medical School · GBRoyal Sussex County Hospital · GBKing's College London · GBUniversity Hospitals Sussex NHS Foundation Trust · GBUniversity of Sussex · GB

Funding

Department of Health PG-0711-25094
6 · The paper itself

Abstract

aimCardiovascular disease (CVD) is common amongst frail older people. The evidence base for CVD commonly excludes older adults with multimorbidity or chronic conditions. Most cardiovascular drugs have the potential to lower blood pressure (BP) and therefore cause medication-related harm (MRH). We aimed to identify key clinical and sociodemographic characteristics associated with MRH in older people taking BP-lowering drugs for whatever indication they were prescribed.

methodsThe PRIME (prospective study to develop a model to stratify the risk of MRH in hospitalised elderly patients in the UK) study investigating the incidence and cost of MRH in older people across Southern England. Adults ≥65 years were recruited from five teaching hospitals at hospital discharge and followed up for 8 weeks. Telephone interviews with study participants, review of primary care records and hospital readmissions were undertaken to identify MRH. PRIME study participants taking BP-lowering drugs (as defined by National Institute for Health and Care Excellence hypertension guidelines) were included in this analysis.

resultsOne hundred and four (12%) study patients experienced a total of 153 MRH events associated with BP-lowering drugs. Patients on four BP-lowering drugs were five times more likely to experience MRH compared to those taking one medication (OR 4.96; 95%CI 1.63-15.13; P = 0.01). Most MRH events were classified 'serious' (80%, n = 123), requiring dose change or treatment cessation. Almost half of MRH were potentially preventable (49%, n = 75).

conclusionPolypharmacy from BP-lowering drugs in older people is associated with preventable harm. Decisions around cardiovascular risk reduction should be carefully considered in view of MRH arising from BP-lowering drugs.

Indexed as

Drug-Related Side Effects and Adverse ReactionsAgedAntihypertensive AgentsBlood PressureHumansPatient DischargeProspective StudiesAntihypertensive Agentscardiovascular diseasefrailtyhypertensionmedication-related harmolder peoplepolypharmacy

Identifiers

PMID35352796
PMCPMC8966023
OpenAlexW4221072218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.